Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | DDR2 | Q16832 | 10/20 | 0.38 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 7/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1571239 | 0.90 | GSK3B (0.41) | ACACBDDR2MAP4K3MAP4K1BRAF | |
| SCHEMBL1571237 | 0.90 | GSK3B (0.41) | ACACBDDR2MAP4K3MAP4K1BRAF | |
| SCHEMBL1571306 | 0.90 | GSK3B (0.41) | ACACBDDR2MAP4K3MAP4K1BRAF | |
| SCHEMBL1870184 | 0.88 | BRAF (0.37) | ACACBDDR2MAP4K3MAP4K1BRAF | |
| SCHEMBL1571982 | 0.86 | DDR2 (0.36) | DDR2MAP4K3MAP4K1BRAFMAPK1 | |
| SCHEMBL1571686 | 0.84 | MAP4K1 (0.40) | DDR2MAP4K3MAP4K1BRAF | |
| SCHEMBL13336170 | 0.84 | MAP4K1 (0.42) | MAP4K3MAP4K1BRAF | |
| SCHEMBL1571377 | 0.84 | BRAF (0.43) | MAP4K3MAP4K1BRAF | |
| SCHEMBL1571733 | 0.82 | BRAF (0.39) | ACACBDDR2MAP4K3MAP4K1BRAF | |
| SCHEMBL1571735 | 0.82 | BRAF (0.39) | ACACBDDR2MAP4K3MAP4K1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307385-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | Novartis AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| WO-2009153313-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2009-12-23 | — | — | WO | disclosed |